Treatment of Refractory Takayasu Arteritis with Tocilizumab: 7 Italian Patients from a Single Referral Center
- 1 November 2013
- journal article
- Published by The Journal of Rheumatology in The Journal of Rheumatology
- Vol. 40 (12), 2047-2051
- https://doi.org/10.3899/jrheum.130536
Abstract
Objective. The aim of our study was to evaluate the safety and the efficacy of tocilizumab (TCZ) for refractory Takayasu arteritis (TA). Methods. We retrospectively assessed the outcome of blocking interleukin (IL)-6 with TCZ in 7 consecutive patients with refractory TA using a combination of clinical and imaging assessment. Results. During a median followup visit at 14 months, 4 patients taking TCZ [including 2 nonresponders to tumor necrosis factor (TNF) inhibitors] achieved clinical response, suggesting a nonredundant role for IL-6 in TA. Inflammatory markers normalized in all patients treated with TCZ. However, vascular progression occurred in 4 patients, suggesting the involvement of other inflammatory pathways and confirming the limitations of erythrocyte sedimentation rate and C-reactive protein for disease activity assessment while taking TCZ. Three patients experienced adverse events and 2 suspended TCZ. Conclusion. TCZ may be effective in a subset of patients with refractory TA, even in cases of unresponsiveness to TNF inhibitors. Inflammatory markers are not valid markers of TA activity on TCZ. Further studies are needed to confirm these preliminary observations.Keywords
This publication has 17 references indexed in Scilit:
- Tocilizumab: a novel therapy for patients with large-vessel vasculitisRheumatology, 2011
- Pathogenesis of Takayasu's arteritis: A 2011 updateAutoimmunity Reviews, 2011
- The value of blocking IL-6 outside of rheumatoid arthritis: current perspectiveCurrent Opinion in Rheumatology, 2011
- Takayasu arteritis—advances in diagnosis and managementNature Reviews Rheumatology, 2010
- Anti-tumour necrosis factor therapy in patients with refractory Takayasu arteritis: long-term follow-upAnnals Of The Rheumatic Diseases, 2008
- Successful treatment of a patient with takayasu arteritis using a humanized anti–interleukin‐6 receptor antibodyArthritis & Rheumatism, 2008
- Takayasu Arteritis: What is the Long-Term Prognosis?Rheumatic Disease Clinics of North America, 2007
- Limitations of therapy and a guarded prognosis in an american cohort of takayasu arteritis patientsArthritis & Rheumatism, 2007
- Serum cytokine profiles and their correlations with disease activity in Takayasu's arteritisRheumatology, 2005
- Interleukin-6 and RANTES in Takayasu ArteritisCirculation, 1999